<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533129</url>
  </required_header>
  <id_info>
    <org_study_id>GSM-022011</org_study_id>
    <nct_id>NCT01533129</nct_id>
  </id_info>
  <brief_title>The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism</brief_title>
  <official_title>Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulhane School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulhane School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study searched for answers to two questions

        1. What is the effect of testosterone replacement therapy on endothelial dysfunction,
           inflammation and insulin resistance?

        2. Regarding the above parameters, is there any difference between daily transdermal
           testosterone implementation and intramuscular injection performed in three weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The alterations in the measures for endothelial functions</measure>
    <time_frame>6 months</time_frame>
    <description>The alterations in Endothelial functions are determined by measuring plazma ADMA levels, as a surrogate. ADMA measurement is pereformed by ELISA kit (Immundiagnotik, Bensheim, Germany)(Catalog Number 7828) with a minimal detection limit of 0.05Âµmol/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The alterations in the measures of insulin resistance</measure>
    <time_frame>6 months</time_frame>
    <description>The alterations in insulin sensitivity are estimated by using the HOMA index by the formula, HOMA-IR = (insulin x glucose)/405.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The alterations in the measures of inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>The alterations in the measures of inflammation are determined by measuring Human Pentraxin-3 levels. ELISA kiti /R&amp;D Systems, Inc. Minneapolis, MN, ABD) (Catalog number DPTX30) with a minimal detection limit of 0.025ng/ml, intraassay CV of 3.8-4.4%, and interassay CV of 4.1-6.1% was used.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Hypogonadotrophic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Daily testosterone transdermal gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectable Testosterone esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosteron 250mg injection per 3-4 weeks for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testogel 50 mg transdermal gel</intervention_name>
    <description>50mg testosterone gel implementation on every night</description>
    <arm_group_label>Daily testosterone transdermal gel</arm_group_label>
    <other_name>Testogel 50mg transdermal gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone 250mg injection</intervention_name>
    <description>The testosterone 250mg ester IM injections performed in three weeks.</description>
    <arm_group_label>Injectable Testosterone esters</arm_group_label>
    <other_name>Sustanon 250 mg amp.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men

          -  Treatment naive

          -  Hypogonadotrophic hypogonadism

        Exclusion Criteria:

          -  Previous history of androgen replacement

          -  Chronic metabolic disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gulhane School of Medicine Department of Endocrinology and Metabolism</name>
      <address>
        <city>Ankara</city>
        <state>Non US</state>
        <zip>06018</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gulhane School of Medicine</investigator_affiliation>
    <investigator_full_name>Alper Sonmez</investigator_full_name>
    <investigator_title>Associate Professor in Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Testosterone replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

